Background characteristics and mHam assay results
| Patient . | Age . | Sex . | Hypercoagulable state . | Autoimmune comorbidity . | Chronic venous insufficiency . | Current ulcers . | mHam assay result . | Mean soluble C5b-9 ± SEM (ng/mL) . |
|---|---|---|---|---|---|---|---|---|
| P1 | 70 | F | None known | Levamisole vasculitis | No | No | Negative | 35.7 ± 8.3 |
| P2 | 79 | F | Triple antiphospholipid antibody positive | Antiphospholipid syndrome | Yes | No | Negative | 54.0 ± 23.3 |
| P3 | 78 | F | None known | None known | Yes | Yes | Negative | 12.3 ± 1.7 |
| P4 | 53 | F | Elevated homocysteine | None known | No | Yes | Negative | 22.3 ± 1.7 |
| P5 | 61 | F | None known | None known | Yes | No | Negative | 24.0 ± 6.7 |
| P6 | 64 | M | History of multiple venous thromboembolic events | None known | Yes | No | Negative | 14.0 ± 3.3 |
| P7 | 41 | M | Plasminogen activator inhibitor mutation | None known | No | Yes | Negative | 4.0 ± 10.0 |
| P8 | 89 | M | Positive anticardiolipin and anti-β-2-GP-I | None known | Yes | Yes | Positive | 34.0 ± 6.7 |
| P9 | 73 | M | None known | Diffuse connective tissue disease | No | No | Negative | 25.7 ± 21.7 |
| P10 | 78 | F | None known | None known | Yes | No | Negative | 44.0 ± 6.7 |
| P11 | 65 | M | Elevated homocysteine | None known | No | Yes | Negative | 29.0 ± 11.7 |
| P12 | 72 | F | None known | None known | No | No | Negative | 2689 ± 1232 |
| P13 | 56 | M | None known | None known | Yes | Yes | Negative | 537.3 ± 483.3 |
| P14 | 68 | F | None known | None known | No | Yes | Negative | 40.7 ± 3.3 |
| P15 | 60 | F | Heterozygous factor V Leiden | None known | Yes | No | Negative | 22.3 ± 1.7 |
| P16 | 65 | F | None known | None known | No | No | Negative | 77.3 ± 36.7 |
| Patient . | Age . | Sex . | Hypercoagulable state . | Autoimmune comorbidity . | Chronic venous insufficiency . | Current ulcers . | mHam assay result . | Mean soluble C5b-9 ± SEM (ng/mL) . |
|---|---|---|---|---|---|---|---|---|
| P1 | 70 | F | None known | Levamisole vasculitis | No | No | Negative | 35.7 ± 8.3 |
| P2 | 79 | F | Triple antiphospholipid antibody positive | Antiphospholipid syndrome | Yes | No | Negative | 54.0 ± 23.3 |
| P3 | 78 | F | None known | None known | Yes | Yes | Negative | 12.3 ± 1.7 |
| P4 | 53 | F | Elevated homocysteine | None known | No | Yes | Negative | 22.3 ± 1.7 |
| P5 | 61 | F | None known | None known | Yes | No | Negative | 24.0 ± 6.7 |
| P6 | 64 | M | History of multiple venous thromboembolic events | None known | Yes | No | Negative | 14.0 ± 3.3 |
| P7 | 41 | M | Plasminogen activator inhibitor mutation | None known | No | Yes | Negative | 4.0 ± 10.0 |
| P8 | 89 | M | Positive anticardiolipin and anti-β-2-GP-I | None known | Yes | Yes | Positive | 34.0 ± 6.7 |
| P9 | 73 | M | None known | Diffuse connective tissue disease | No | No | Negative | 25.7 ± 21.7 |
| P10 | 78 | F | None known | None known | Yes | No | Negative | 44.0 ± 6.7 |
| P11 | 65 | M | Elevated homocysteine | None known | No | Yes | Negative | 29.0 ± 11.7 |
| P12 | 72 | F | None known | None known | No | No | Negative | 2689 ± 1232 |
| P13 | 56 | M | None known | None known | Yes | Yes | Negative | 537.3 ± 483.3 |
| P14 | 68 | F | None known | None known | No | Yes | Negative | 40.7 ± 3.3 |
| P15 | 60 | F | Heterozygous factor V Leiden | None known | Yes | No | Negative | 22.3 ± 1.7 |
| P16 | 65 | F | None known | None known | No | No | Negative | 77.3 ± 36.7 |
Anti-β-2-GP-I, anti–β-2-glycoprotein I antibody; F, female; M, male; SEM, standard error of the mean.